AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2561147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once a day)
Number of subjects: 16
Study 2561147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30289165 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional discrimination relational training task
Number of subjects: 21
Study 30289165 — intervention group
Group type: COMPARATOR
Intervention: Relational training plus defusion procedure
Number of subjects: 21
Study 28609608 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled voriconazole (40 mg b.i.d. for 2 days)
Number of subjects: 12
Study 28609608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole (400 mg on day 1, 200 mg on day 2, b.i.d.)
Number of subjects: 12
Study 25805212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 30
Study 25805212 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study 23350870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=35)
Number of subjects: 73
Study 23350870 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 21315002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hengyan medicinal recipe 50 ml, 3 times daily for 7 days
Number of subjects: 45
Study 21315002 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with western medicine
Number of subjects: 45
Study 19692911 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during physical therapy sessions
Number of subjects: 39
Study 19692911 — intervention group
Group type: COMPARATOR
Intervention: No Virtual Reality (no VR) during physical therapy sessions
Number of subjects: 39
Study 17338829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation followed by resection
Number of subjects: 0
Study 17338829 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery
Number of subjects: 0
Study 15355469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat allergen peptide immunotherapy
Number of subjects: 0
Study 15355469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15355469 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+) CD25(+) T cells (both before and after therapy)
Number of subjects: 0
Study 11695713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation of acyclovir (200mg)
Number of subjects: 12
Study 11695713 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of acyclovir (100mg)
Number of subjects: 12
Study 9333591 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg2+)
Number of subjects: 0
Study 2022560 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (0.07 U/kg body wt daily)
Number of subjects: 24
Study 7211966 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 7211966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31995784 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) over 12 months
Number of subjects: 231
Study 30108337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT)
Number of subjects: 20
Study 30108337 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 20
Study 30108337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT) and Sham therapy
Number of subjects: 20
Study 28935843 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1,400 mg cycles 2-8)
Number of subjects: 576
Study 28935843 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2 cycles 1-8)
Number of subjects: 576
Study 28935843 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 576
Study 28935843 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 576
Study 25738573 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL protocol
Number of subjects: 128
Study 25056361 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol vaccine
Number of subjects: 0
Study 25056361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukoral vaccine
Number of subjects: 0
Study 22491729 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management program (relaxation breathing and progressive muscle relaxation, twice a day)
Number of subjects: 61
Study 22491729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 22491729 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management program
Number of subjects: 61
Study 20484772 — intervention group
Group type: EXPERIMENTAL
Intervention: Free grip choice for both hands
Number of subjects: 0
Study 20484772 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinstructed grip for right hand and free choice for left hand
Number of subjects: 0
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the video
Number of subjects: 567
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the hand mirror
Number of subjects: 567
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower card
Number of subjects: 567
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: American Cancer Society brochure
Number of subjects: 567
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample photographs
Number of subjects: 567
Study 18406492 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding the health educator helpful
Number of subjects: 567
Study 15840076 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of music intervention
Number of subjects: 64
Study 15840076 — intervention group
Group type: COMPARATOR
Intervention: Rest period (Control)
Number of subjects: 64
Study 11936019 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRActHIB vaccine
Number of subjects: 131
Study 10357402 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, 120 mg/m2 i.v. on Days 1-3; 5-fluorouracil, 500 mg/m2 i.v. on Days 1-3; folinic acid, 300 mg/m2 i.v. on Days 1-3; GM-CSF 250 microg/m2/day for 14 days if Grade 4 neutropenia occurred.
Number of subjects: 30
Study 10357402 — intervention group
Group type: COMPARATOR
Intervention: Courses without GM-CSF
Number of subjects: 30
Study 10357402 — intervention group
Group type: EXPERIMENTAL
Intervention: Courses with GM-CSF
Number of subjects: 30
Study 8825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (50 mg daily intravenous for 1 week, followed by 21 mg daily oral for week 2, and 7 mg daily oral for weeks 3-4)
Number of subjects: 331
Study 8825274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 8825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 331
Study 8825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (subgroup receiving treatment within 6 hours)
Number of subjects: 331
Study 8825274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup receiving treatment within 6 hours)
Number of subjects: 331
Study 1582280 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms of triamcinolone acetonide daily
Number of subjects: 143
Study 1582280 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 micrograms of triamcinolone acetonide daily
Number of subjects: 143
Study 1582280 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 micrograms of triamcinolone acetonide daily
Number of subjects: 143
Study 1582280 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 143
Study 3932250 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour tubing change
Number of subjects: 2
Study 3932250 — intervention group
Group type: COMPARATOR
Intervention: No tubing change
Number of subjects: 2
Study 30670528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 30670528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29329910 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise test (GXT) until exhaustion with different delay groups (0, 30, 60, 90 min after GXT)
Number of subjects: 95
Study 29329910 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 35 min at 45-50%, 65-70%, or 85-90% of HRmax
Number of subjects: 95
Study 26847689 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (75 µg, intravenously)
Number of subjects: 20
Study 26847689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, intravenously)
Number of subjects: 20
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma glucose
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: No components of MetS
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: At least two components of MetS
Number of subjects: 2443
Study 25261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with MetS
Number of subjects: 2443
Study 22381024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 102
Study 22381024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glycemic load (RGL) diet
Number of subjects: 102
Study 22381024 — intervention group
Group type: COMPARATOR
Intervention: Standard portion-controlled (PC) diet
Number of subjects: 102
Study 21164547 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 8)
Number of subjects: 16
Study 21164547 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 8)
Number of subjects: 16
Study 16716604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg IV bolus)
Number of subjects: 0
Study 16716604 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 16716604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg IV bolus) repeated 7 hours later
Number of subjects: 0
Study 15618341 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of quadriceps and hamstring muscles (three 30 second stretches)
Number of subjects: 20
Study 12002498 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stainless-steel screws
Number of subjects: 23
Study 12002498 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly coated with HA screws
Number of subjects: 23
Study 12002498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully coated HA screws
Number of subjects: 23
Study 10213463 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2 treatment for 8 weeks
Number of subjects: 27
Study 10213463 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (14 patients)
Number of subjects: 27
Study 10213463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (13 patients)
Number of subjects: 27
Study 7799019 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 resection with extended lymphadenectomy
Number of subjects: 473
Study 7799019 — intervention group
Group type: COMPARATOR
Intervention: R1 resection with limited lymphadenectomy
Number of subjects: 473
Study 2256758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation starting on postoperative day 1 (group A)
Number of subjects: 34
Study 2256758 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 34
Study 2256758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation (group A)
Number of subjects: 34
Study 6770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OC)
Number of subjects: 35
Study 6770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Neogynon (a type of Oral Contraceptive)
Number of subjects: 35
Study 6770409 — intervention group
Group type: COMPARATOR
Intervention: Loop (Intrauterine Contraception)
Number of subjects: 35
Study 31517847 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (WC)
Number of subjects: 0
Study 28166848 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 126
Study 28166848 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational group
Number of subjects: 126
Study 25877963 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 400 mg
Number of subjects: 636
Study 25877963 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg
Number of subjects: 636
Study 23646839 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk feedback intervention
Number of subjects: 292
Study 23646839 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation
Number of subjects: 292
Study 23646839 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk feedback intervention + Self-affirmation manipulation
Number of subjects: 292
Study 20615930 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg/day)
Number of subjects: 43
Study 20615930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20615930 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 43
Study 19505589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral DOT (directly observed therapy)
Number of subjects: 77
Study 19505589 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 77
Study 17998682 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 1
Study 17998682 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision of metastasis
Number of subjects: 1
Study 15070666 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 66
Study 15070666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 11334204 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term leukocyte filtration during reperfusion by release of the aortic crossclamp
Number of subjects: 0
Study 11334204 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different filtration concepts
Number of subjects: 0
Study 9783600 — intervention group
Group type: EXPERIMENTAL
Intervention: Presacral drainage
Number of subjects: 48
Study 9783600 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 48
Study 7837397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 units intravenously before CPB and before declamping of aorta)
Number of subjects: 36
Study 7837397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 units added in the priming solution)
Number of subjects: 36
Study 7837397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 36
Study 7837397 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36
Study 2452940 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs started within 8 days after 131I
Number of subjects: 206
Study 2452940 — intervention group
Group type: COMPARATOR
Intervention: Radioactive iodine (131I) alone
Number of subjects: 206
Study 28918083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone (FML)
Number of subjects: 41
Study 28918083 — intervention group
Group type: COMPARATOR
Intervention: polyvinyl alcohol (PA)
Number of subjects: 41
Study 26936270 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment scaling rehabilitation
Number of subjects: 120
Study 26936270 — intervention group
Group type: COMPARATOR
Intervention: Usual care rehabilitation
Number of subjects: 120
Study 25546524 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with low-dose bupivacaine and fentanyl
Number of subjects: 100
Study 25546524 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 100
Study 23024014 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly alcohol intake (10 units/week increase)
Number of subjects: 12700
Study 20394042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 94
Study 20394042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 20394042 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 94
Study 20394042 — intervention group
Group type: COMPARATOR
Intervention: No AKI
Number of subjects: 94
Study 18477075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by hourly urine output (HUO Group, n=12)
Number of subjects: 24
Study 18477075 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation guided by intrathoracic blood volume index (ITBVI Group, n=12)
Number of subjects: 24
Study 18477075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HUO and ITBVI)
Number of subjects: 24
Study 15909462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring with low dose progesterone (1.8 g)
Number of subjects: 29
Study 15909462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring with high dose progesterone (3.6 g)
Number of subjects: 29
Study 15909462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring (both doses)
Number of subjects: 29
Study 12913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 321
Study 12913766 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 321
Study 10594396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg o.d.)
Number of subjects: 133
Study 10594396 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg b.d.)
Number of subjects: 133
Study 10594396 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg o.d.) and Ranitidine (300 mg b.d.)
Number of subjects: 133
Study 8591120 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of dialysis
Number of subjects: 0
Study 8591120 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea kinetic modeling
Number of subjects: 0
Study 8591120 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer membranes and higher levels of dialysis
Number of subjects: 0
Study 1719288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisoprolol (20 mg) at rest
Number of subjects: 8
Study 1719288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisoprolol (20 mg) with iterative stress tests
Number of subjects: 8
Study 1719288 — intervention group
Group type: COMPARATOR
Intervention: Placebo during exercise tests
Number of subjects: 8
Study 84441 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC alone or in combination with other cytotoxic agents (Oncovin, Bleomycin, Adriblastin)
Number of subjects: 24
Study 30756406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at improving parent-school cooperation
Number of subjects: 2746
Study 30756406 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 control schools)
Number of subjects: 2746
Study 30756406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 2746
Study 31173898 — intervention group
Group type: EXPERIMENTAL
Intervention: Decidua stromal cells (DSCs) infused at a median dose of 1.2 (range, 0.9 to 2.9) × 10^6 cells/kg body weight, median of 2 doses given 1 week apart.
Number of subjects: 21
Study 30353893 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 2
Study 30353893 — intervention group
Group type: COMPARATOR
Intervention: Alveogyl
Number of subjects: 2
Study 25381202 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 52
Study 25381202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24517061 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming Shen, enhancing Yang, invigorating qi, and nourishing blood method (WSEYIQNBM) combined artificial cycle therapy
Number of subjects: 96
Study 24517061 — intervention group
Group type: COMPARATOR
Intervention: Western medicine artificial cycle therapy
Number of subjects: 96
Study 21942916 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U
Number of subjects: 0
Study 21942916 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U (pre-procedural use)
Number of subjects: 0
Study 21942916 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U (routine prevention)
Number of subjects: 0
Study 19288321 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 50
Study 19288321 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 50
Study 18064333 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC)
Number of subjects: 150
Study 18064333 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow-mononuclear cells (BM-MNC)
Number of subjects: 150
Study 15234477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected impacts at 15.4 m/s2
Number of subjects: 10
Study 15234477 — intervention group
Group type: COMPARATOR
Intervention: Expected impacts at 15.4 m/s2
Number of subjects: 10
Study 15234477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected impacts
Number of subjects: 10
Study 11528491 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional rehabilitation food
Number of subjects: 8
Study 11528491 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid nutritional rehabilitation food
Number of subjects: 8
Study 11528491 — intervention group
Group type: COMPARATOR
Intervention: Comparison of solid vs liquid
Number of subjects: 8
Study 10189849 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 3000
Study 7917743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia (mean dose 10.6 MAC-h)
Number of subjects: 21